Corbus Pharmaceuticals’ Post

Got some interesting data related to targeted drugs in cancer? Or maybe you have an idea for a review paper on this topic? The Cancers MDPI special issue "Research on Targeted Drugs in Cancer" is now open for submissions! Learn more here: https://lnkd.in/g-ii5VND #callforpapers #targetedtherapy #oncology #cancer #clinicaltrials #regulatory #drugdevelopment

We are pleased to report Q3 earnings today. This quarter has been exciting for Calidi Biotherapeutics, highlighted by: - New data on the first patient dosing in our CLD-101 recurrent high grade glioma trial at City of Hope. - New preclinical data on CLD-201 presented at Society for Immunotherapy of Cancer (SITC) #sitc23. - The introduction of new members to our Board of Directors and Executive Team. We are encouraged by our continued clinical progress and are looking forward to closing 2023 out strong. Read more here: https://lnkd.in/dam44dxu #calidi #stemcells #q3earnings #clinicaltrials #curecancer

Exciting Update: A multitude of new #Oncology #Drugs are currently in the #Pipeline, promising advancements in cancer treatment. Challenge Ahead: #Research Sites, already grappling with complexity and volume, face the risk of becoming even more overwhelmed. The solution? Embracing new #technologies to streamline processes! Our Solutions: - Inteliquet, an IQVIA business streamlines Trial Matching & Screening, ensuring patients are matched with the most suitable trials. - Our IQVIA #EMRtoEDC Solution streamlines data collection, making it easier for research sites to manage and analyze data. Interested in learning more about how we can assist? Or perhaps you’d like to connect with our teams at the upcoming #ASCO conference? Don’t hesitate to reach out. We’re here to help navigate the future of oncology research together. Mui Van Zandt Alan Frederickson PMP® Sneha Kishnani, PMP James Coutcher John Pappa Kelly Smith Sabrina Cheema Anastasia Pargulski, MPH

Check out the latest trends in Oncology with the new IQVIA Institute report!

Just published! IQVIA Institute's The Global Oncology Trends 2024 report, download from link below.

Exciting news for the healthcare community! The IQVIA Institute has released its latest report, "Global Oncology Trends 2024," providing valuable insights into cancer research and treatment. Key highlights include: Profiles of the latest data on cancer incidence and survival rates Updates on research and development in oncology, including key mechanisms and targets Metrics on clinical development productivity Trends in the use of novel mechanisms for specific cancer types Spending dynamics expected over the next five years #Oncology #CancerResearch #LifeSciences #GlobalHealth #Oncology #CancerResearch #LifeSciences #GlobalHealth

Q&A: The potential of immuno-oncology - a view from the R&D department Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing in... https://lnkd.in/eHFZyizw #BioTech #science

Shout out to Drs. Nelson and Subbiah for their astutely written reply to the Conley et al. editorial on the “adscopal effect” in the high-impact journal, Molecular Cancer Therapeutics. Read it here: https://bit.ly/3SqI55Y   An “abscopal effect” classically refers to the regression of distant tumors outside the treatment field of radiation therapy. By contrast, the “adscopal effect," a term coined by Conley et al. describes the shrinkage of distant, noninjected visceral lesions mediated by the oncolytic adenovirus, AdAPT-001.   As Nelson and Subbiah point out, what differentiates oncolytic adenoviruses like AdAPT-001 from other oncolytic viruses is that they “piggyback” on lymphocytes and erythrocytes, which are thought to shield them from the presence of neutralizing antibodies so that these adenoviruses reach and transduce non-injected tumors.   Our expectation is that if AdAPT-001 continues to make waves in hard-to-treat tumors like sarcomas, the novel term “adscopal effect” will become conventionalized and formally enter the clinical lexicon.  

Yesterday we have just posted the Global Oncology Trends 2024 Report oncology trends report. Follow the link below and be informed about the current situation and next year dynamics. #datascience #clinicalresearch #oncology